Oncolytics Biotech is trading 11% up at $0.54, with its October 14, 2026 announcement offering possible company-specific context; it did not attribute the gain to the news. - Enrollment in GOBLET is complete; final Cohort 4 results are expected in Q4 2026, and initial Cohort 5 results in the first half of 2027. - Cohort 4 median overall survival exceeds expectations, and all cohorts enrolling the required patients met their prespecified efficacy criteria. - The broader biotech sector and major indexes were lower, so they do not explain the stock’s rise.